Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	
Ward:	NHI:
Epoetin beta	a
	chronic renal failure (tick boxes where appropriate)
and	Patient in chronic renal failure
and	Haemoglobin is less than or equal to 100g/L
	O Patient does not have diabetes mellitus and O Glomerular filtration rate is less than or equal to 30ml/min
or	
	O Patient has diabetes mellitus
	Glomerular filtration rate is less than or equal to 45ml/min
and	Patient is on haemodialysis or peritoneal dialysis
Re-assessmen	myelodysplasia* It required after 12 months (tick boxes where appropriate)
O	Patient has a confirmed diagnosis of myelodysplasia (MDS)
and and	Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent
0	Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS)
and	Other causes of anaemia such as B12 and folate deficiency have been excluded
and	Patient has a serum epoetin level of < 500 IU/L
and	The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week
Re-assessmen	DN – myelodysplasia* It required after 2 months (tick boxes where appropriate)
and	The patient's transfusion requirement continues to be reduced with epoetin treatment
O	Transformation to acute myeloid leukaemia has not occurred
and	The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week

I confirm that the above details are correct:

Signed: Date:

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Page 2

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIBER		PATIENT:				
Name	e:		Name:				
Ward	:		NHI:				
Epoetin beta - continued							
INITIATION – all other indications							
Prer	equisites	(tick boxes where appropriate)					
	O	Haematologist					
	For use in patients where blood transfusion is not a viable treatment alternative						
	and	*Note: Indications marked with * are unapproved indications					

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	